Previous close | 0.4600 |
Open | 0.4700 |
Bid | 0.2000 |
Ask | 0.5000 |
Strike | 6.00 |
Expiry date | 2024-05-17 |
Day's range | 0.2000 - 0.5500 |
Contract range | N/A |
Volume | |
Open interest | 1.67k |
Helen Thackray, Chief Research & Development Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 14, 2024.
On May 13, 2024, Steven Galson, a Director at BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 21,940 shares of the company, as reported in a recent SEC Filing.
Charles Gayer, Chief Commercial Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 13, 2024.